Novel Drug Controls Glucose, but May Have Cancer Risk

ADA 2011 — SAN DIEGO — The novel SGLT2 inhibitor dapagliflozin produced superior glycemic control over placebo when added to metformin, although there were faint signals of bladder and breast cancer cases in the drug groups, researchers said here.


< Back to Listings